Introduction
Nitrosamine impurities are potentially carcinogenic chemicals that can form during drug production or storage. These compounds have raised significant concerns in the pharmaceutical industry due to their link to cancer risks. Uncertainty about their presence in drug products, coupled with a lack of clear safety thresholds, has created substantial regulatory and operational challenges.
Some manufacturers have been forced to conduct additional studies or even withdraw their products from the market due to the detection of nitrosamines. This situation has not only disrupted supply chains but also led to drug shortages, impacting patient care. Establishing acceptable intake (AI) limits for nitrosamines, defined as safe daily exposure levels, is an urgent priority for regulators and manufacturers alike.
However, determining AI limits for nitrosamine drug substance-related impurities (NDSRIs) is complex. These impurities are specific to each drug, and safety data for establishing AI limits is often unavailable. Regulators have traditionally relied on conservative AI limits or data from structurally similar compounds, but these approaches have proven inadequate, resulting in drug availability disruptions. To address these issues, the CPCA for Nitrosamine was developed, offering a more robust and structured solution. CPCA for Nitrosamine play important role for nitrosamine .
What is Carcinogenic Potency Categorization Approach (CPCA)
The CPCA for Nitrosamine provides a scientific framework to streamline the evaluation of nitrosamine impurities. This method, developed by the FDA and adopted internationally, predicts carcinogenic potency by analyzing the chemical structure of nitrosamines. By categorizing nitrosamines into one of five potency categories (PCs), each with defined AI limits, the CPCA creates a balance between ensuring drug safety and maintaining availability.
Key Elements of the CPCA:
- Chemical Structure Analysis: This step focuses on α-hydroxylation, a metabolic process critical for nitrosamine activation. The structural analysis identifies features that contribute to their carcinogenic potential.
- Structural Feature Scoring: The CPCA evaluates both activating and deactivating molecular features. Activating features increase cancer risk, while deactivating features reduce it.
- Potency Scoring Formula:
Potency Score = α-Hydrogen Score + Deactivating Feature Scores + Activating Feature Scores.
This formula quantifies the risk level, with higher scores indicating reduced carcinogenic potential. - Potency Categories (PCs): Nitrosamines are assigned to categories (PC 1–5) based on their scores, with AI limits ranging from 18 ng/day for the highest risk to 1500 ng/day for the lowest risk.
Take the first step to implementation of nitrosamine guidelines with us
Contact us today to take the first step towards compliance and operational excellence in the pharmaceutical industry.
Set an appointmentBasics of CPCA Categories
The CPCA for Nitrosamine simplifies the complex process of assessing nitrosamine impurities by categorizing them based on carcinogenic risk. This scientific method not only ensures patient safety but also allows manufacturers to avoid unnecessary disruptions.
How Does the CPCA Work?
CPCA assigns nitrosamines to potency categories (PCs) based on their chemical structure and potential cancer risk:
- PC 1 → Highest carcinogenic risk: These nitrosamines require the strictest AI limits (around 18 ng/day).
- PC 5 → Lowest carcinogenic risk: These impurities have the least cancer-causing potential, allowing AI limits of up to 1500 ng/day.
The categorization relies on molecular features, including α-hydrogens and functional groups, which either activate or deactivate the cancer-causing potential of the compound.
Detailed Breakdown of CPCA Potency Categories
- Features: Nitrosamines in this category typically have multiple α-hydrogens and strong activating groups (e.g., benzyl groups).
- AI Limit: Around 18 ng/day.
- Example: A nitrosamine with 2,2 α-hydrogens and an activating benzyl group but no deactivating features.
- Features: These nitrosamines exhibit moderate activating features but lack strong deactivating characteristics.
- AI Limit: Higher than PC 1 but still low.
- Example: A nitrosamine with 0,3 α-hydrogens and a methyl group on the β-carbon.
- Features: Compounds in this category show a balance of weak activating and deactivating features.
- AI Limit: Around 150 ng/day.
- Example: A nitrosamine with 1,2 α-hydrogens and a hydroxyl group on the β-carbon.
- Features: Strong deactivating features dominate in this category, reducing cancer-causing potential.
- AI Limit: Higher than PC 3.
- Example: A nitrosamine with 1,1 α-hydrogens and a carboxylic acid group.
- Features: These compounds have no significant activating features and strong deactivating groups.
- AI Limit: Up to 1500 ng/day.
- Example: A nitrosamine with 0,0 α-hydrogens or a tertiary α-carbon.
How CPCA Assigns Categories
The Carcinogenic Potency Categorization Approach (CPCA) follows a simple step-by-step process to assess and categorize the risk of nitrosamine impurities based on their chemical structure. Here’s how it works in a slightly more detailed explanation:
Question: Does the molecule have features that strongly reduce or eliminate the potential to cause cancer?
Examples of Low-Risk Features:
- 0,0 α-Hydrogen: The molecule has no α-hydrogens, which are essential for cancer-causing activation.
- Tertiary α-Carbon: The structure detoxifies the molecule, preventing harmful interactions with DNA.
- 0,1 or 1,1 α-Hydrogens: These features disfavor activation.
If any of these features are present:
- Result: The molecule is automatically assigned to Potency Category 5 (PC 5), indicating the lowest cancer risk.
- If these features are not present, move to Step 2.
If the molecule does not meet the low-risk criteria, its potential risk is calculated using a Potency Score. This score is determined by adding the contributions of:
- Activating Features (Risk-Increasing):
- Examples:
- Aryl Group: Adds a small amount of risk (-1).
- Methyl Group on β-Carbon: Slightly increases risk (-1).
- Examples:
- Deactivating Features (Risk-Reducing):
- Examples:
- Carboxylic Acid Group: Strongly reduces risk (+3).
- N-Nitroso Group in Certain Ring Structures: Reduces risk moderately (+2).
- Examples:
- α-Hydrogen Features:
- The number and distribution of α-hydrogens directly impact the molecule’s potential for activation. For example, 2,2 α-hydrogens indicate a high risk of activation.
Formula: Potency Score=α-Hydrogen Score+ Deactivating Feature Scores+ Activating Feature Scores
- High Potency Score: Lower carcinogenic risk.
- Low Potency Score: Higher carcinogenic risk.
The calculated Potency Score is compared to pre-defined thresholds to place the molecule in one of the following Potency Categories (PCs):
- PC 1: Highest risk, with the strictest acceptable intake (AI) limit (18–26.5 ng/day).
- PC 2: High risk, slightly less strict AI limit.
- PC 3: Moderate risk, AI limit around 150 ng/day.
- PC 4: Low risk, higher AI limit.
- PC 5: Lowest risk, with the highest AI limit (up to 1500 ng/day).
- Step 1: Identify if the molecule has low-risk features (e.g., no α-hydrogens or detoxifying structures).
- If yes, assign to PC 5.
- If no, proceed to Step 2.
- Step 2: Calculate the Potency Score by summing activating and deactivating features.
- Step 3: Use the Potency Score to assign a Potency Category (PC 1–5) with corresponding AI limits.
This systematic approach ensures nitrosamines are categorized based on their cancer-causing potential, allowing for better safety management in pharmaceuticals.
Importance of the CPCA for Nitrosamine
The adoption of the CPCA for Nitrosamine by regulatory agencies like the FDA has streamlined safety evaluations. Its structured approach eliminates the need for exhaustive studies while ensuring patient safety.
- Patient Safety: Ensures that nitrosamines in drugs are within safe limits.
- Streamlined Approvals: Offers a faster method for assessing nitrosamine safety without lengthy toxicology studies.
- Drug Availability: Minimizes supply chain disruptions by enabling clear regulatory pathways.
Advantages of the CPCA
- Scientific Rigor: Uses robust carcinogenicity data for accurate risk predictions.
- Efficiency: Reduces the need for time-consuming toxicology studies.
- Flexibility: Applicable to known and hypothetical nitrosamines.
- Transparency: Provides clear AI limits, fostering predictable regulatory outcomes.
Conclusion
The CPCA for Nitrosamine is a transformative method that balances safety and accessibility. By leveraging chemical structure analysis and predictive scoring, it offers a practical solution to a complex regulatory challenge. As the pharmaceutical industry embraces this approach, it sets a precedent for innovation in safety assessments.
As scientific understanding evolves, continuous refinements to the CPCA are expected. Collaborative efforts between international regulatory bodies aim to enhance the accuracy and applicability of this framework, ensuring it remains a critical tool for managing nitrosamine risks.
References
- https://www.fda.gov/drugs/spotlight-cder-science/determining-recommended-acceptable-intake-limits-n-nitrosamine-impurities-pharmaceuticals
- Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities
- Control of Nitrosamine Impurities in Human Drugs
- EMA Nitrosamine Guidance
- FDA Nitrosamine Guidance
- Control of nitrosamines in human drugs
- https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications
- https://www.linkedin.com/pulse/what-nitrosamines-pharmaceutical-industry-alireza-zarei-r9lie/
- https://www.linkedin.com/pulse/role-big-data-nitrosamine-risk-assessment-sagar-pawar-qnkxe/
- https://zamann-pharma.com/2024/08/05/6-steps-to-reduce-nitrosamines-impurities-in-pharma-industry/
- https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/referral-procedures-human-medicines/nitrosamine-impurities
Sagar Pawar
Sagar Pawar, a Quality Specialist at Zamann Pharma Support, brings over 11 years of experience in Quality domain for the pharmaceutical and medical technology industries. Specializing in qualification, validation, Computer System Validation (CSV), and Nitrosamine activities, Sagar is currently focused on enhancing the Zamann Service portfolio by developing and implementing robust strategies to address Nitrosamine-related challenges. Outside of work, Sagar enjoys trekking and cooking. Connect with Sagar on LinkedIn to discuss topics related to equipment qualification, GMP Compliance and Nitrosamine-related challenges.
